Development of a novel gene therapy to treat diabetic macular oedema
Lead Research Organisation:
University of Cambridge
Department Name: Clinical Neurosciences
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
People |
ORCID iD |
| Keith Martin (Primary Supervisor) | |
| Michael Whitehead (Student) |
Studentship Projects
| Project Reference | Relationship | Related To | Start | End | Student Name |
|---|---|---|---|---|---|
| MR/R502303/1 | 01/10/2017 | 30/04/2022 | |||
| 1944187 | Studentship | MR/R502303/1 | 01/10/2017 | 30/09/2021 | Michael Whitehead |
| Description | CHARACTERISATION OF EXOSOME-ASSOCIATED AAV2 AS A NOVEL GENE THERAPY TECHNOLOGY TO ENABLE REPEATED GENE TRANSFER IN MOUSE MODELS OF DIABETIC MACULAR OEDEMA? |
| Amount | £9,000 (GBP) |
| Funding ID | G103197 |
| Organisation | Novo Nordisk Foundation |
| Sector | Charity/Non Profit |
| Country | Denmark |
| Start | 06/2019 |
| End | 06/2020 |
| Description | Enhanced neuroprotection of the optic nerve using exosome-associated capsid mutant AAV2 |
| Amount | £10,000 (GBP) |
| Organisation | Sight Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2020 |
| End | 01/2020 |
| Description | Repeated Gene Transfer using Exosome-associated AAV2 Gene Therapy Modalities |
| Amount | £7,500 (GBP) |
| Funding ID | G104080 |
| Organisation | Addenbrooke's Charitable Trust (ACT) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 12/2019 |
| End | 11/2020 |
| Description | Assessment of purity of ExoAAV2 gene therapies |
| Organisation | University of Cambridge |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | We provided the viruses to be tested for purity. |
| Collaborator Contribution | The collaborators brought the purity testing kits and performed the experiments. |
| Impact | We have been able to test the purity of our viruses in a way that we have not been able to before. This data will be used in our publication which we hope to submit by the end of 2020. |
| Start Year | 2020 |
| Description | Assessment of role of Trim21 on AAV2 neutralisation |
| Organisation | University of Cambridge |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | We investigated the role of Trim21 in mediating the neutralisation of AAV2. I undertook all of the cell culture and neutralising antibody experiments. |
| Collaborator Contribution | The collaborators provided all of the cell lines for the experiments. They also provided access to the flow cytometer for the assessment of the role of Trim21. |
| Impact | The project is still very much in its infancy but we have some interesting preliminary data. |
| Start Year | 2020 |
| Description | Inhibition of neutralising antibody responses using anti-CD138 Abs |
| Organisation | University of California, Los Angeles (UCLA) |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | We will test anti-CD138 Abs in our mouse model of anti-AAV2 neutralising antibody responses. |
| Collaborator Contribution | The collaborators will provide the Abs for us to work with |
| Impact | We have not yet commenced the experiments, however, the collaboration has been informally agreed |
| Start Year | 2020 |
| Description | Testing B and Tl cell responses to AAV in the spleens |
| Organisation | University of Cambridge |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | We have supplied splenic tissue to the Sage group at Cambridge cardiovascular. |
| Collaborator Contribution | The Sage group have assessed B and T cell activation using flow cytometry. |
| Impact | We have been pleased with the data so far. We are continuing our collaboration to look at dendritic cell changes in the spleens after AAV injection. |
| Start Year | 2021 |